Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment

PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI and MICHAEL MIAN
Anticancer Research September 2014, 34 (9) 5121-5125;
PATRIZIA MONDELLO
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patriziamondello@hotmail.it
VINCENZO PITINI
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARMELA ARRIGO
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ENRICO DERENZINI
2L. and A. Seràgnoli Institute of Hematology, S. Orsola-Malpighi Hospital, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL MIAN
3Department of Hematology, Hospital S. Maurizio, Bolzano/Bozen, Italy
4Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity whose prognosis for high-risk patients is poor. Aggressive salvage treatments to improve patient outcome have been unsatisfactory. Therefore, we evaluated the efficacy of yttrium-90-ibritumomab tiuxetan (Zevalin®; 90Y-IT) consolidation after early salvage chemotherapy with autologous stem cell transplantation. Thirty-seven patients with intermediate-high risk DLBCL not in complete remission (CR) after three cycles of rituximab, cyclophosphomide, doxorubicin, vincristine and prednisone (R-CHOP) were assessed retrospectively. After early salvage treatment, 70% achieved CR and 30% partial remission. Twenty patients underwent additional consolidation with 90Y-IT. During the 3-year follow-up, 50% in the 90Y-IT-treated group experienced relapse compared to 82.3% in the other cohort (p=0.002). Progression- and disease-free survival were significantly longer in the 90Y-IT group. However, probably due to the relatively short follow-up period, no difference in overall survival was observed. 90Y-IT consolidation after early salvage chemotherapy improves treatment responses and reduces the percentage of relapses without significant additional toxicities.

  • 90Y-Ibritumomab tiuxetan
  • salvage therapy
  • DLBCL
  • lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma subtype, accounting for approximately 25-30% of new cases of non-Hodgkin's lymphoma (NHL) (1). Combination therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) has been considered the gold standard for more than 25 years (1). Nevertheless, estimated progression-free survival (PFS) and overall survival (OS) at three years were only 40% and 50%, respectively. In the past decade, the addition of rituximab (R-CHOP), a chimeric monoclonal antibody to the protein CD20, has led to an outstanding survival improvement for patients with DLBCL, which is why R-CHOP has become the new standard-of-care for this aggressive disease (2, 3). Despite this approach, due to the high percentage of relapses, the prognosis for patients with high-risk DLBCL, namely those with an elevated International Prognostic Index (IPI), bulky disease, involvement of the central nervous system or testes, is still poor, with a 5-year OS of less than 50% (4). Current salvage treatments, including autologous stem cell transplantation (ASCT), are not able to cure most patients (5). Thus, since first-line treatment intensification (6-8) has not improved outcome, new salvage strategies are needed and the addition of radioimmunotherapy could be a valid option. Indeed, it has proven to be efficient in relapsed/refractory aggressive DLBCL (9-11). However, preliminary results of therapy with yttrium-90-ibritumomab tiuxetan (Zevalin®; 90Y-IT) after ASCT are conflicting and the analyzed cohorts were too small to draw any conclusions (12, 13).

Herein, we provide the first direct comparison of patients with intermediate/high-risk DLBCL after early salvage treatment including ASCT who either underwent 90Y-IT consolidation or did not.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Treatment algorithm.

Patients and Methods

Patients. From July 2006 to September 2012, all 37 consecutive patients affected by intermediate/high-risk DLBCL indicated for early salvage treatment were retrospectively assessed at the G. Martino University Hospital in Messina. A histological review according to the current WHO classification (14) was performed on all cases at the Seràgnoli Istitute of Hematology, University of Bologna. As required by the inclusion criteria, all patients had stage III/IV disease, an IPI >1 (15) and a performance status <3. Consolidation with 90Y-IT was proposed to all patients who were considered fit enough, regardless of the type of response to treatment. Overall, 20 patients agreed to treatment intensification, while the others did not and were considered as a control group.

The local Ethical Committee approved this analysis (Prot. E 49/13) and all patients were required to sign an informed consent form.

Treatment plan. None of the 37 patients achieved a complete response (CR) after three cycles R-CHOP-21 (16 patients with partial response (PR), 21 patients with stable disease (SD)) which is why they underwent early salvage immuno-chemotherapy with three or four cycles of R-DHAP (rituximab, cisplatin, cytarabine, dexamethasone) (5). Successive stem cell mobilization consisted of cyclophosphamide (4-7 g/m2) on day +1, rituximab (375 mg/m2) on day +2 and lenograstim 5 μg/kg die from day +3 until stem cell collection (Figure 1). In cases of insufficient harvest (<9×106 CD34+ cells/kg), additional leukapheresis was performed after mobilization with cytarabine (3-4 g/m2 days 1-4) and lenograstim 5 μg/kg from day +5 die until stem cell collection. Three weeks after stem cell collection, all patients underwent three tandem high-dose cytarabine administrations (12 to 24 g/m2, every 21 days), followed by rituximab and reinfusion on day +2 of at least 2×106/kg CD34+ cells (16, 17). Six to 10 weeks after ASCT, 20 patients received an additional consolidation treatment with 90Y-IT, while the remaining 17 did not. 90Y-IT was administered according to the international standard, namely rituximab at 250 mg/m2 on day 1 and on day 8 followed by 14.8 MBq (0.4 mCi)/kg of 90Y-IT after the last rituximab dose. In order to prevent infectious complications, patients routinely received granulocyte colony-stimulating factor once their total white blood cell count was ≤2,000/mm3 until full recovery and erythropoietin was administered when the hemoglobin decreased to less than 10 g/dl. Antibiotic and antifungal prophylaxis was also administered.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patients' characteristics.

Treatment response was assessed after three cycles of R-CHOP, after ASCT and after 90Y-IT where applicable. It consisted of a complete physical examination, blood testing, bone marrow aspirate and biopsy in case of bone marrow involvement at diagnosis, as well as Positron emission tomography-computed tomography (18).

Statistical analyses. Chi-square test was performed to assess the significance of differences between categorical variables. OS, PFS and disease-free survival (DFS) were plotted as curves using the Kaplan–Meier method and were defined as the time from diagnosis until death from any cause, as time from diagnosis until disease progression or death from any cause, and as time from the achievement of a CR to relapse or death as a result of lymphoma or acute toxicity of treatment, respectively (18). Log-rank test was employed to assess the impact on survival of categorical variables. A p-value of <0.05 was considered as statistically significant. Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) software v.17.0.1 (SPSS, Chicago, IL, USA), MedCalc (version 11.0; MedCalc Software Acacialaan, Ostend, Belgium) software and the GraphPad Prism (version 5.0; GraphPad Software, Inc., San Diego, CA, USA) package.

Results

Clinical characteristics at time of diagnosis. Overall, the median age at time of diagnosis was 54.3 years (range=34-64 years). A female predominance was observed (20/37, 54.1%). As required by the inclusion criteria, all patients had stage III/IV disease. Twenty-nine patients (78.3%) had B symptoms and lactate dehydrogenase was elevated in 34 patients (91.8%). Only a minority (13; 35.1%) had bulky disease (Table I). Except for extranodal disease that prevailed in the 90Y-IT-treated group (100% vs. 72%; p=0.011), clinical features at the time of diagnosis were similar in the two treatment groups and no statistically significant differences were observed (Table I).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Treatment response according to therapy.

Treatment and response. After three cycles of R-CHOP-21, 16 patients achieved a PR, and 21 had SD. Hence, early salvage immunochemotherapy with R-DHAP was initiated. As mentioned above, stem cell collection was performed with lenograstim after the last cycle and a median number of 3.15×106/kg CD34+ cells (range=2.01-4.10×106/kg) was harvested in the 90Y-IT group compared to 3.03×106/kg CD34+ cells (range=2.01-4.90×106/kg) in the other one. Only three patients had a sufficient CD34+ cell harvest after cyclophosphamide and therefore the remaining 34 patients underwent a second mobilization with high-dose cytarabine with peripheral blood stem cell collection. After three tandem ASCTs, 20 patients agreed to 90Y-IT consolidation: seven of them were in CR and 11 in PR, while the remaining were in CR and refused treatment intensification. After 90Y-IT, all 20 patients were in CR (Table II). After completion of the whole program, four out of five in the second group with initial high-risk achieved CR and one a PR.

Consolidation with 90Y-IT was well-tolerated. Reversible hematological toxicity, mainly consisting of grade 3 neutropenia and thrombocytopenia, occurred in eight patients (40%). Not a single case of febrile neutropenia was registered. Five patients (25%) developed grade 2 anemia. Transfusions of platelets or red blood cells were not required. About half of the patients experienced only mild-to-moderate fatigue following 90Y-IT consolidation therapy. Of note, no case of thyroid dysfunction or secondary malignancy occurred. There were no treatment-related deaths.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Relapse and status at the last follow-up according to treatment.

Follow-up. After a median DFS time of three years (range=8-36 months), 22/37 (59.4%) patients eventually experienced disease relapse: 10/20 (50%) in the 90Y-IT-treated group and 12/17 (70.5%) in the other group (p=0.002). Overall, 21 of them underwent further treatments. The median response duration differed significantly between both groups, 52 months in the 90Y-IT-treated group and 25 in the other (p=0.001). At the last follow-up, 15 patients were alive in CR, 13 with disease and nine died with disease. (Table III) Treatment intensification significantly prolonged median DFS (4.3 years versus 2.0 years, p=0.001) and PFS (5.1 years versus 2.7 years, p=0.007; Figure 2A and B). However, probably due to the relatively short follow-up period, no difference in OS was observed (Figure 2C).

Discussion

The role of 90Y-IT consolidation after salvage chemotherapy with ASCT in patients with high-risk DLBCL has not yet been established, although it influences positively the outcome in patients with relapsed/refractory DLBCL (10, 19). Herein, we provide evidence that 90Y-IT consolidation after salvage treatment clearly reduces the percentage of relapses and improves PFS and DFS in these patients.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier analysis of disease-free survival (DFS) (A; p=0.001), Progression-free survival (PFS) (B; p=0.007) and Overall survival (OS) (C; p=0.507) according to Zevalin ® consolidation.

The strengths of the present analysis were the central histological revision and the homogeneous treatment, although these patients were treated outside a clinical trial. The main limit of our study was its retrospective nature.

90Y-IT consolidation was able to induce a CR in all patients who were in PR (55%) after salvage chemotherapy and ASCT. A similar experience was published by Ria et al. who administered 90Y-IT as consolidation therapy to seven patients with high-risk NHL and residual disease after at least three months from ASCT and five patients achieved a CR with minimal additional toxicity (13). In a recent phase II trial, Han et al. evaluated the efficacy and safety of tandem consolidation with 90Y-IT and HDCT with ASCT in 11 patients with high-risk DLBCL and with at least a PR after induction (12). In contrast to our data, none of the five patients with PR converted to CR after 90Y-IT but they suffered disease progression. However, since no adequate salvage therapy was administered before 90Y-IT consolidation the informative value of these data is limited.

In the present study, 90Y-IT was very well tolerated and no patient experienced life-threatening toxicity. Adverse events were limited to neutropenia and thrombocytopenia, both grade 3, (n=8; 40%) and grade 2 anemia (n=5; 25%). Of note, no case of febrile neutropenia was observed. However, previous trials (12, 20) reported a much higher hematological toxicity rate, most likely due to the large number of previous treatment lines.

Y90-IT consolidation after ASCT led to a significant increase in the duration of response because the median DFS was significantly higher in this group (4.3 years) when compared to the control cohort (2.0 years; p=0.002). This could be explained by better disease eradication by radioimmunotherapy. These results are in line with what was reported by Ria et al. who recorded a median response duration of four years (range=2-5 years) (13). However, in the trial by Han et al. during the median follow-up period of 18.1 months, nine out of 11 patients (82%) suffered disease progression (12). In the present analysis, PFS also differed significantly between the groups, suggesting that 90Y-IT not only reduces the risk of relapse but also the number of deaths. Indeed, OS was clearly longer in patients who underwent 90Y-IT consolidation, without achieving statistical significance. The relatively low number of patients assessed for this analysis could explain this observation. Again, our data in contrast with those published by Han et al (12) who reported a detrimental PFS and OS.

In conclusion, 90Y-IT consolidation after salvage chemotherapy is able to improve treatment response, reduce the percentage of relapses and improve PFS and DFS. Therefore 90Y-IT might be able to eliminate minimal residual disease, at least in some cases. However, these data have to be confirmed in a prospective trial.

Acknowledgements

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Footnotes

  • ↵* Present address: Lymphoma Department, Memorial Sloan Kettering, NY, U.S.A. Tel: +1 9173535554, e-mail: mondellp{at}mskcc.org

  • Received May 28, 2014.
  • Revision received July 5, 2014.
  • Accepted July 7, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Michallet AS,
    2. Coiffier B
    : Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 23(1): 11-23, 2009.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tilly H
    : Treatment options in non-Hodgkin lymphomas. Rev Prat 20;60(1): 69-74, 2010.
    OpenUrl
  3. ↵
    1. Keating GM
    : Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 30;70(11): 1445-1476, 2010.
    OpenUrl
  4. ↵
    1. Feugier P,
    2. Van Hoof A,
    3. Sebban C,
    4. Solal-Celigny P,
    5. Bouabdallah R,
    6. Fermé C,
    7. Christian B,
    8. Lepage E,
    9. Tilly H,
    10. Morschhauser F,
    11. Gaulard P,
    12. Salles G,
    13. Bosly A,
    14. Gisselbrecht C,
    15. Reyes F,
    16. Coiffier B
    : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18): 4117-4126, 2005.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Gisselbrecht C,
    2. Glass B,
    3. Mounier N,
    4. Singh Gill D,
    5. Linch DC,
    6. Trneny M,
    7. Bosly A,
    8. Ketterer N,
    9. Shpilberg O,
    10. Hagberg H,
    11. Ma D,
    12. Brière J,
    13. Moskowitz CH,
    14. Schmitz N
    : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27): 4184-4190, 2010.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Cortelazzo S,
    2. Tarella C,
    3. Gianni AM,
    4. Barbui T,
    5. Ladetto M,
    6. Barbui AM,
    7. Rossi A,
    8. Corradini P,
    9. Di Nicola M,
    10. Patti C,
    11. Mulé A,
    12. Zanni M,
    13. Zoli V,
    14. Billio A,
    15. Gallamini A,
    16. Di Raimondo F,
    17. Ferreri A JM,
    18. Pizzolo G,
    19. La Nasa G,
    20. Leoni P,
    21. Semenzato G,
    22. Frezzato M,
    23. Flenghi L,
    24. Scarano M,
    25. Masciulli A,
    26. Marchioli R,
    27. Rambaldi A
    : Chemoimmunotherapy with R-CHOP or high dose sequential therapy with autologous stem cell transplantation (R-HDS) for high risk diffuse large b-cell lymphomas patients: results of the randomized R-HDS0305 trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). ASH Annu Meet Abstr 120: 746, 2012.
    OpenUrl
    1. Gianni AM,
    2. Berinstein NL,
    3. Evans PA,
    4. López-Guillermo A,
    5. Solano C
    : Stem-cell transplantation in non-Hodgkin's lymphoma: Improving outcome. Anticancer Drugs 13(suppl 2): S35-S42, 2002.
    OpenUrlPubMed
  7. ↵
    1. Tomblyn M
    : Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control 19(3): 196-203, 2012.
    OpenUrlPubMed
  8. ↵
    1. Botto B,
    2. Bellò M,
    3. Benevolo G,
    4. Cabras MG,
    5. Castellino C,
    6. Chiappella A,
    7. Fioritoni G,
    8. Freilone R,
    9. Martelli M,
    10. Orsucci L,
    11. Pregno P,
    12. Scapoli P,
    13. Tonso A,
    14. Bisi G,
    15. Vitolo U,
    16. Gallo E
    : Radioimmunotherapy (RIT) with 90Y-IT (90Y-IT) for the treatment of relapsed or resistant aggressive diffuse large B-cell lymphoma (DLBCL) heavily pretreated with rituximab-chemotherapy: A GIMURELL experience. ASH Annu Meet Abstr 110: 4478, 2007.
    OpenUrl
  9. ↵
    1. Witzig TE,
    2. Molina A,
    3. Gordon LI,
    4. Emmanouilides C,
    5. Schilder RJ,
    6. Flinn IW,
    7. Darif M,
    8. Macklis R,
    9. Vo K,
    10. Wiseman GA
    : Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium90 ibritumomab tiuxetan. Cancer 109(9): 1804-1810, 2007.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Morschhauser F,
    2. Radford J,
    3. Van Hoof A,
    4. Botto B,
    5. Rohatiner AZ,
    6. Salles G,
    7. Soubeyran P,
    8. Tilly H,
    9. Bischof-Delaloye A,
    10. van Putten WL,
    11. Kylstra JW,
    12. Hagenbeek A
    : 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 31(16): 1977-1983, 2013.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Han EJ,
    2. Lee SE,
    3. Kim SH,
    4. Sohn HS,
    5. Jung SE,
    6. Park G,
    7. Choi BO,
    8. Lee SN,
    9. Yang SW,
    10. Han K,
    11. Cho SG
    : Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (90Y-IT®) for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol 90(9): 1075-1082, 2011.
    OpenUrlPubMed
  12. ↵
    1. Ria R,
    2. Musto P,
    3. Reale A,
    4. Guariglia R,
    5. Iodice G,
    6. Dammacco F,
    7. Vacca A
    : 90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma. J Nucl Med 52(6): 891-895, 2011.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Swerdlow SH,
    2. Campo E,
    3. Harris NL,
    4. Jaffe ES,
    5. Pileri SA,
    6. Stein H,
    7. Thiele J,
    8. Vardiman JW
    : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition. Lyon, France: IARC Press, 2008.
  14. ↵
    1. The International Non Hodgkin's Lymphomas Prognostic Factors Project
    : A predictive model for aggressive non Hodgkin's lymphoma. N Engl J Med 329(14): 987-994, 1993.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gianni AM,
    2. Magni M,
    3. Martelli M,
    4. Di Nicola M,
    5. Carlo-Stella C,
    6. Pilotti S,
    7. Rambaldi A,
    8. Cortelazzo S,
    9. Patti C,
    10. Parvis G,
    11. Benedetti F,
    12. Capria S,
    13. Corradini P,
    14. Tarella C,
    15. Barbui T
    : Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102(2): 749-755, 2003.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Devizzi L,
    2. Guidetti A,
    3. Tarella C,
    4. Magni M,
    5. Matteucci P,
    6. Seregni E,
    7. Chiesa C,
    8. Bombardieri E,
    9. Di Nicola M,
    10. Carlo-Stella C,
    11. Gianni AM
    : High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 10;26(32): 5175-5182, 2008.
    OpenUrl
  17. ↵
    1. Cheson BD,
    2. Pfistner B,
    3. Juweid ME,
    4. Gascoyne RD,
    5. Specht L,
    6. Horning SJ,
    7. Coiffier B,
    8. Fisher RI,
    9. Hagenbeek A,
    10. Zucca E,
    11. Rosen ST,
    12. Stroobants S,
    13. Lister TA,
    14. Hoppe RT,
    15. Dreyling M,
    16. Tobinai K,
    17. Vose JM,
    18. Connors JM,
    19. Federico M,
    20. Diehl V,
    21. International Harmonization Project on Lymphoma
    : Revised response criteria for malignant lymphoma 25(5): 579-586, 2007.
    OpenUrl
  18. ↵
    1. Morschhauser F,
    2. Illidge T,
    3. Huglo D,
    4. Martinelli G,
    5. Paganelli G,
    6. Zinzani PL,
    7. Rule S,
    8. Liberati AM,
    9. Milpied N,
    10. Hess G,
    11. Stein H,
    12. Kalmus J,
    13. Marcus R
    : Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110(1): 54-58, 2007.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Buchegger F,
    2. Prior JO,
    3. Allenbach G,
    4. Baechler S,
    5. Kosinski M,
    6. Helg C,
    7. Chalandon Y,
    8. Ratib O,
    9. Delaloye AB,
    10. Ketterer N
    : Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance. Clin Nucl Med 37(10): 960-964, 2012.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (9)
Anticancer Research
Vol. 34, Issue 9
September 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI, MICHAEL MIAN
Anticancer Research Sep 2014, 34 (9) 5121-5125;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI, MICHAEL MIAN
Anticancer Research Sep 2014, 34 (9) 5121-5125;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • 90Y-Ibritumomab tiuxetan
  • Salvage therapy
  • DLBCL
  • lymphoma
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire